| |
 |
CARDIOVASCULAR
BIOTHERAPEUTICS, INC. (OTCBB: CVBT) |
 |
Dear StockUpTicks Reader,
CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) is a company
that we have followed with great interest for several years. As shareholders
ourselves, we are excited about the long-term prospects of CVBT and the
promise of its technology to provide treatment for cardiovascular disease,
the leading cause of death worldwide. If you don't have CVBT on your
watch list, we encourage you to add it now. As you can see in the chart
below the stock is experiencing a breakout. Price and volume have
been rising precipitously for the past few trading days. We are not
sure what is bringing new interest to this equity but there couldn't be
a better time to start paying close attention to this CVBT.
Recent News From
CVBT:
Thursday January
8, 2009, 8:00 am EST
CVBT Opens Two Additional Sites
for Its ACORD Phase II Heart Trial
LAS VEGAS, Jan. 8
/PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin
Board: CVBT - News) announced today that two additional hospitals in
the United States opened for patient enrollment for its ACORD Phase II
clinical trial for the treatment of severe coronary heart disease. The
sites are University of California Medical Center San Diego, CA and Holy
Cross Hospital, Fort Lauderdale, FL.
Mercy Hospital Fairfield
(Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for
enrollment in early September, and are working in collaboration to screen
and treat patients in the trial. They treated their first patient in support
of the trial in mid November 2008.
CVBT now has five sites
that are open for enrollment and intends to announce additional sites as
they open for screening patents.
About CardioVascular
BioTherapeutics
CVBT (OTCBB: CVBT -
News) is a biopharmaceutical company developing human FGF-1 for cardiovascular
diseases characterized by inadequate blood flow to a tissue or organ. In
addition to the Phase II trial it is conducting in patients with severe
coronary heart disease, the company has two FDA-authorized clinical trials
in the areas of impaired wound healing seen in diabetics and in patients
suffering from peripheral artery disease of the legs. An additional study
is being conducted in patients with chronic back pain who may have perfusion
defects to their spine. For more information about CardioVascular BioTherapeutics,
Inc. please visit http://www.cvbt.com.
Media Contact:
Allison Caplan,
CardioVascular BioTherapeutics, Inc.
(702) 839-7200, acaplan@cvbt.com
Investor Contact:
Amy Montano Gordon,
CardioVascular BioTherapeutics, Inc.
(702) 839-7220, investorrelations@cvbt.com
<<<Spacer>>>
|
Other
articles of interest on CardioVascular BioTherapeutics |
|
|
CardioVascular BioTherapeutics, Inc. is featured in this issue
of the medical journal Nature
Biotechnology, an example of a smaller, nimble biotech
company that is ideally positioned to quickly adapt its development and
commercialization processes to the current environment, centralizing healthcare
value and capitalizing on the opportunities under the new review system.
You may view the February 2008
Nature Biotechnology article HERE
|
<<<Spacer>>>
<<<Spacer>>>
|
New Treatment for Heart Transplant
Hopefuls
An experimental treatment is
giving desperately ill heart patients a new lease on life.
By Lisa Collier Cool - View
Article HERE |
<<<Spacer>>>
|
About
CardioVascular BioTherapeutics |
|
CardioVascular BioTherapeutics Inc. (OTCBB: CVBT) is a biopharmaceutical
company focused on developing protein drug candidates to be used in the
treatment of cardiovascular disease, the worldwide leading cause of death.
The Company is developing injectable and topical formulations of its active
pharmacological ingredient (API) to facilitate the growth of new blood
vessels (angiogenesis) in the heart, tissues and organs that have been
compromised by impaired blood supply (hypoxia, ischemia). The Company’s
API contains FGF-1141 a human protein manufactured using a proprietary
technology. FGF-1 stimulates the growth and proliferation of the
three main cell types of blood vessels; endothelial cells, smooth muscles
cells and pericytes.
The Company’s lead drug candidate successfully completed initial clinical
trials in Germany during the 1990s, with no drug-related adverse events
and a statistically significant increase in localized blood vessel growth
(and perfusion) both in patients also receiving coronary by-pass procedures
and in patients with severe coronary heat disease (CHD) receiving FGF-1,
as the sole therapy. Enrollment and treatment has been completed in an
FDA authorized Phase I study with CVBT-141A, administered via injection
in severe CHD patients. The protocol design for the Phase II trial (CVBT-141H)
has been approved by the FDA and is planned to initiate in 2008.
CardioVascular BioTherapeutics, Inc. is committed to conducting additional
clinical trials to establish the positive effect of FGF-1141 aimed at improving
the quality of life for those suffering from heart disease, stroke, diabetic
wounds, or peripheral artery disease, and pledges to continue exploration
for additional applications of FGF-1.
In
the U.S. Alone 60 Million People Suffer From Some Form of Cardiovascular
Disease
>>
|
Meeting a Significant Need |
|
- 38% of all deaths in the United States are caused
by cardiovascular disease
- 13.2 million suffer from coronary artery disease
- 4.8 million people in the U.S. have suffered strokes
- 7.8 million people in the U.S. will have a heart
attack this year
- Every 35 seconds someone will suffer a heart attack
or strokea
>>>>>>>>>>>>>>>>>>Overview>>>>>>>>>>>>>>>>>>>>>Market
Opportunities
| CVBT is committed to exploring medical applications
for our drugs which contain the active pharmaceutical ingredient of FGF-1.
To achieve this goal, we conduct ongoing research and continually collaborate
with internationally recognized researchers in the areas of angiogenesis
and growth factors.
We place a high priority on communicating information
about our clinical trials to physicians, patients, investors, and other
interested parties.
CVBT has posted protocol information for its
Phase II severe coronary heart disease (CHD) clinical trial on this website.
For additional information regarding this trial as well as our other trials,
you may also visit the National Institutes of Health's (NIH) Clinical Trials
website at www.clinicaltrials.gov.
|
|
Clinical
Foundation: Two clinical trials were conducted with CVBT-141A in the
1990s in Germany; the first with 40 patients of which, 20 were in the control
group, and the second with 20 patients all of whom received treatment.
These trials had no adverse events and met their clinical endpoints.
Unique Regenerative
Approach: The Company’s focus is to treat diseases regeneratively by
stimulating angiogenesis, vasculogenesis and neurogenesis locally with
injectable and topical drug candidates containing the API, rather than
attempting to repair blocked blood vessels or damaged tissue.
Patent Position: The Company has IP with 5 issued U.S. Patents, and 5 foreign patent applications
related to U.S. patents. The Company continuously focuses on opportunities
to extend the IP portfolio.
"Our opportunities continue to expand.
In the process of investigating new possible applications for our drug
candidate, we have identified many new potential medical applications that
number well beyond what Dr. Stegmann and his colleagues had previously
imagined."
Daniel C. Montano - CVBT
Chairman, President, and CEO
>>
|
Protein
vs Gene Therapy |
|
Initial clinical success with CVBT-141A as a protein therapy in the
1990s is in stark contrast to problems encountered when attempting angiogenesis
using gene therapy. Gene-based therapies may result in side effects due
to the virus-mediated gene transfer, difficulties integrating the therapeutic
DNA (gene) into the genome of target cells, unregulated and variable protein
expression leading to angiogenesis at sites other than those targeted,
and difficulty ensuring localized release and activity. Further, gene-based
approaches may be limited by the inflammatory host response induced by
the viral vectors and the transient nature of the intervention.
<<<Spacer>>>
a
|
CVBT Leadership |
|
a
Daniel C. Montano
Co-Founder, Chairman of the
Board, President & Chief Executive Officer
Daniel C. Montano brings a wide range of management
experience to his roles, having served as CEO of 14 operating companies
in industries such as real estate, high technology, medical technology,
biotechnology, food products, financial institutions, and service companies.
From 1981 until 2004, Montano was a member of the Board of Directors of
Helen of Troy, Ltd, a Texas company with revenue of over $450 million.
He also spent 30 years as an investment banker, retiring from that business
in 1998. Montano received his MBA from the University of Southern California
and his undergraduate degree from California State University, Los Angeles.
Mickael A. Flaa
Vice President and Chief Financial
Officer
Mr. Flaa is a CPA and a retired partner from KPMG.
He joined CVBT in June 2003. Prior to these positions, he served as Interim
Chief Financial Officer for publicly-held Breakaway Solutions, Inc., and
as Chief Financial Officer and member of the Board of Directors for Sunbelt
Integrated Trade Services, Inc.
Mr. Flaa is VP & CFO of Phage Biotechnology
Corporation, a related party. He also remains involved in the management
and/or board of directors of several additional ventures: Onnam Gaming,
and Gestalt, LLC. Flaa spent 22 years in various management positions with
KPMG Peat Marwick LLP, where he was elected to partnership in 1990. He
worked with clients in fields including health care, technology, utilities,
transportation and energy. Flaa received his undergraduate degree from
Central Washington University.
John (Jack) William Jacobs, Ph.D.
Vice President, Chief Scientific
Officer and Chief Operating Officer
Dr. Jacobs joined CVBT in April 2000. Previously
he served as Director of Basic Research at the Hitachi Chemical Research
Center in Irvine, California, and as an adjunct Professor of Biological
Chemistry at University of California-Irvine’s College of Medicine.
Earlier in his career, Dr. Jacobs worked for Merck
& Co. Inc. as the head of their Department of Biological Chemistry
at the Merck Sharp & Dohm Research Laboratories in West Point, Pennsylvania,
and as Assistant Professor of Medicine and Biochemistry at the University
of Texas Health Center. Dr. Jacobs received his Ph.D. in molecular biology
from the Washington University School of Medicine, and his undergraduate
degree in Chemistry from Davidson College.
Kenneth A. Thomas, Ph.D.
Vice President, Research and
Development
Dr. Thomas brings to CVBT over two decades of
experience at the Merck Research Laboratories in scientific research and
pharmaceutical development of therapeutic proteins and small molecule enzyme
inhibitors. His scientific and managerial expertise includes the
areas of biological chemistry, molecular biology, cell biology and animal
pharmacology spanning cardiology, endocrinology, dermatology, ophthalmology
and oncology. He has served on The Journal of Biological Chemistry
editorial board, co-organized national and international meetings on growth
factors, angiogenesis, protein kinases and signal transduction, and has
over 90 publications and 40 issued patents.
While at Merck, Dr. Thomas initiated, built and
directed the preclinical biology programs leading to six angiogenic and
anti-angiogenic development candidates. This work was based on his
initial discovery and characterization of FGF-1 and research on functionally
related angiogenic growth factors and their receptors.
Dr. Thomas received a B.S. degree in Chemistry
from the University of Delaware and a Ph.D. in Biochemistry from Duke University
followed by postdoctoral fellowships at the National Institutes of Health
and Washington University in St. Louis.
a a
|
Financial Highlights For CVBT |
|
Recent Trade: $0.49 (01/28/08)
52 Week Range: $0.25 - $1.90
Avg Vol (3m): 340,952
Approx. Market Cap: $75.80M
Shares Outstanding: 154,696,907 as of Nov 10, 2008
To view the latest 10Q from on the SEC Web site, click Here
a
|
To Contact CVBT |
|
CardioVascular BioTherapeutics,
Inc.
1635 Village Center Circle
Suite 250
Las Vegas, NV 89134
Phone: (702) 839-7200
investorrelations@cvbt.com
Investor Relations Contact:
Media Contact:
Allison Caplan,
CardioVascular BioTherapeutics,
Inc.
(702) 839-7200, acaplan@cvbt.com
Investor Contact:
Amy Montano Gordon,
CardioVascular BioTherapeutics,
Inc.
(702) 839-7220, investorrelations@cvbt.com
*** The Bull is Running. ***
There
may never be a better time to feature YOUR company
to
over 1 MILLION investors.
To learn
more about our programs email us directly at info@stockupticks.com
Stockupticks
Safe Harbor Statement: Statements contained in this document,
including those pertaining to estimates and related plans, potential mergers
and acquisitions, estimates, growth, establishing new markets, expansion
into new markets and related plans other than statements of historical
fact, are forward-looking statements subject to a number of uncertainties
that could cause actual results to differ materially from statements made.
StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated
(MP). MP provides no assurance as to the subject company's plans
or ability to effect any planned and/or proposed actions. MP has no first-hand
knowledge of management and therefore cannot comment on its capabilities,
intent, resources, nor experience and makes no attempt to do so. Statistical
information, dollar amounts, and market size data was provided by the subject
company and related sources believed by MP to be reliable, but MP provides
no assurance, and none is given, as to the accuracy and completeness of
this information.
Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated
(MP). The information, opinions and analysis contained herein are
based on sources believed to be reliable but no representation, expressed
or implied, is made as to its accuracy, completeness or correctness.
Past performance is no guarantee of future results. This report is a paid
advertisement and is for information purposes only and should not be used
as the basis for any investment decision. MP
has been granted twenty thousand restricted shares of CVBT common stock
by CardioVascular BioTherapeutics Inc. for preparation and distribution
of this report and other advertising services. This constitutes
a conflict of interest as to MP’s ability to remain objective in its communication
regarding the subject company. Write or call MP for detailed disclosure
as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways
17595 Harvard Ave., Suite C519 Irvine, CA 92614. MP is not
an investment advisor and this report is not investment advice. This information
is neither a solicitation to buy nor an offer to sell securities but is
a paid advertisement. Information contained herein contains forward-looking
statements and is subject to significant risks and uncertainties, which
will affect the results. The opinions contained herein reflect our
current judgment and are subject to change without notice. MP and/or its
affiliates, associates and employees from time to time may have either
a long or short position in securities mentioned. Information contained
herein may not be reproduced in whole or in part without the express written
consent of Market Pathways Financial Relations Incorporated. |
|
